Loading…

Pharmacological Characterization of the Human P2Y13 Receptor

The P2Y 13 receptor has recently been identified as a new P2Y receptor sharing a high sequence homology with the P2Y 12 receptor as well as similar functional properties: coupling to G i and responsiveness to ADP ( Communi et al., 2001 ). In the present study, the pharmacology of the P2Y 13 receptor...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmacology 2003-07, Vol.64 (1), p.104-112
Main Authors: Marteau, Frederic, Le Poul, Emmanuel, Communi, David, Communi, Didier, Labouret, Catherine, Savi, Pierre, Boeynaems, Jean-Marie, Gonzalez, Nathalie Suarez
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 112
container_issue 1
container_start_page 104
container_title Molecular pharmacology
container_volume 64
creator Marteau, Frederic
Le Poul, Emmanuel
Communi, David
Communi, Didier
Labouret, Catherine
Savi, Pierre
Boeynaems, Jean-Marie
Gonzalez, Nathalie Suarez
description The P2Y 13 receptor has recently been identified as a new P2Y receptor sharing a high sequence homology with the P2Y 12 receptor as well as similar functional properties: coupling to G i and responsiveness to ADP ( Communi et al., 2001 ). In the present study, the pharmacology of the P2Y 13 receptor and its differences with that of the P2Y 12 receptor have been further characterized in 1321N1 cells (binding of [ 33 P]2-methylthio-ADP (2MeSADP) and of GTPγ[ 35 S]), 1321N1 cells coexpressing Gα 16 [AG32 cells: inositol trisphosphate (IP 3 ) measurement, binding of GTPγ[ 35 S]) and Chinese hamster ovary (CHO)-K1 cells (cAMP assay)]. 2MeSADP was more potent than ADP in displacing [ 33 P]2MeSADP bound to 1321N1 cells and increasing GTPγ[ 35 S] binding to membranes prepared from the same cells. Similarly, 2MeSADP was more potent than ADP in stimulating IP 3 accumulation after 10 min in AG32 cells and increasing cAMP in pertussis toxin-treated CHO-K1 cells stimulated by forskolin. On the other hand, ADP and 2MeSADP were equipotent at stimulating IP 3 formation in AG32 cells after 30 s and inhibiting forskolininduced cAMP accumulation in CHO-K1 cells. These differences in potency cannot be explained by differences in degradation rate, which in AG32 cells was similar for the two nucleotides. When contaminating diphosphates were enzymatically removed and assay of IP 3 was performed after 30 s, ATP and 2MeSATP seemed to be weak partial agonists of the P2Y 13 receptor expressed in AG32 cells. The stimulatory effect of ADP on the P2Y 13 receptor in AG32 cells was antagonized by reactive blue 2, suramin, pyridoxal-phosphate-6-azophenyl-2′,4′disulfonic acid, diadenosine tetraphosphate, and 2-(propylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C67085MX), but not by N 6 -methyl 2′-deoxyadenosine 3′,5′-bisphosphate (MRS-2179) (up to 100 μM). The most potent antagonist was N 6 -(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (ARC69931MX) (IC 50 = 4 nM), which behaved in a noncompetitive way. The active metabolite of clopidogrel was unable to displace bound 2MeSADP at concentrations up to 2 μM.
doi_str_mv 10.1124/mol.64.1.104
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73399754</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73399754</sourcerecordid><originalsourceid>FETCH-LOGICAL-h152t-8a561ff8189a012e45cb7625b8fafb79f1c3955f2ad4809786e921dc61f7b75a3</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRbK3ePEsuekvc2ewneJGiVihYREFPy2a720SSbtwkSP31Bqp4Ggae92WeQegccAZA6HUT6ozTDDLA9ABNgRFIMQAcoinGhKdSsbcJOum6D4yBMomP0QSIBAacT9HNqjSxMTbUYVNZUyfzcTe2d7H6Nn0VtknwSV-6ZDE0ZpusyDvkybOzru1DPEVH3tSdO_udM_R6f_cyX6TLp4fH-e0yLcdr-lQaxsF7CVIZDMRRZgvBCSukN74QyoPNFWOemDWVWAnJnSKwtmNIFIKZfIau9r1tDJ-D63rdVJ11dW22LgydFnmulGB0BC9-waFo3Fq3sWpM3Ok_3xG43ANltSm_quh0---_05xq0OMf8x9xEmLJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73399754</pqid></control><display><type>article</type><title>Pharmacological Characterization of the Human P2Y13 Receptor</title><source>Free Full-Text Journals in Chemistry</source><creator>Marteau, Frederic ; Le Poul, Emmanuel ; Communi, David ; Communi, Didier ; Labouret, Catherine ; Savi, Pierre ; Boeynaems, Jean-Marie ; Gonzalez, Nathalie Suarez</creator><creatorcontrib>Marteau, Frederic ; Le Poul, Emmanuel ; Communi, David ; Communi, Didier ; Labouret, Catherine ; Savi, Pierre ; Boeynaems, Jean-Marie ; Gonzalez, Nathalie Suarez</creatorcontrib><description>The P2Y 13 receptor has recently been identified as a new P2Y receptor sharing a high sequence homology with the P2Y 12 receptor as well as similar functional properties: coupling to G i and responsiveness to ADP ( Communi et al., 2001 ). In the present study, the pharmacology of the P2Y 13 receptor and its differences with that of the P2Y 12 receptor have been further characterized in 1321N1 cells (binding of [ 33 P]2-methylthio-ADP (2MeSADP) and of GTPγ[ 35 S]), 1321N1 cells coexpressing Gα 16 [AG32 cells: inositol trisphosphate (IP 3 ) measurement, binding of GTPγ[ 35 S]) and Chinese hamster ovary (CHO)-K1 cells (cAMP assay)]. 2MeSADP was more potent than ADP in displacing [ 33 P]2MeSADP bound to 1321N1 cells and increasing GTPγ[ 35 S] binding to membranes prepared from the same cells. Similarly, 2MeSADP was more potent than ADP in stimulating IP 3 accumulation after 10 min in AG32 cells and increasing cAMP in pertussis toxin-treated CHO-K1 cells stimulated by forskolin. On the other hand, ADP and 2MeSADP were equipotent at stimulating IP 3 formation in AG32 cells after 30 s and inhibiting forskolininduced cAMP accumulation in CHO-K1 cells. These differences in potency cannot be explained by differences in degradation rate, which in AG32 cells was similar for the two nucleotides. When contaminating diphosphates were enzymatically removed and assay of IP 3 was performed after 30 s, ATP and 2MeSATP seemed to be weak partial agonists of the P2Y 13 receptor expressed in AG32 cells. The stimulatory effect of ADP on the P2Y 13 receptor in AG32 cells was antagonized by reactive blue 2, suramin, pyridoxal-phosphate-6-azophenyl-2′,4′disulfonic acid, diadenosine tetraphosphate, and 2-(propylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C67085MX), but not by N 6 -methyl 2′-deoxyadenosine 3′,5′-bisphosphate (MRS-2179) (up to 100 μM). The most potent antagonist was N 6 -(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (ARC69931MX) (IC 50 = 4 nM), which behaved in a noncompetitive way. The active metabolite of clopidogrel was unable to displace bound 2MeSADP at concentrations up to 2 μM.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/mol.64.1.104</identifier><identifier>PMID: 12815166</identifier><language>eng</language><publisher>United States: American Society for Pharmacology and Experimental Therapeutics</publisher><subject>Adenosine Diphosphate - pharmacology ; Adenosine Triphosphate - analogs &amp; derivatives ; Adenosine Triphosphate - pharmacology ; Animals ; Cell Membrane - drug effects ; Cell Membrane - metabolism ; CHO Cells ; Cricetinae ; Cyclic AMP - metabolism ; Female ; GTP-Binding Protein alpha Subunits, Gi-Go - pharmacology ; Guanosine 5'-O-(3-Thiotriphosphate) - metabolism ; Humans ; Inositol Phosphates - metabolism ; Kinetics ; Receptors, Purinergic P2 - drug effects ; Receptors, Purinergic P2 - metabolism ; Thionucleotides - pharmacology</subject><ispartof>Molecular pharmacology, 2003-07, Vol.64 (1), p.104-112</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12815166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marteau, Frederic</creatorcontrib><creatorcontrib>Le Poul, Emmanuel</creatorcontrib><creatorcontrib>Communi, David</creatorcontrib><creatorcontrib>Communi, Didier</creatorcontrib><creatorcontrib>Labouret, Catherine</creatorcontrib><creatorcontrib>Savi, Pierre</creatorcontrib><creatorcontrib>Boeynaems, Jean-Marie</creatorcontrib><creatorcontrib>Gonzalez, Nathalie Suarez</creatorcontrib><title>Pharmacological Characterization of the Human P2Y13 Receptor</title><title>Molecular pharmacology</title><addtitle>Mol Pharmacol</addtitle><description>The P2Y 13 receptor has recently been identified as a new P2Y receptor sharing a high sequence homology with the P2Y 12 receptor as well as similar functional properties: coupling to G i and responsiveness to ADP ( Communi et al., 2001 ). In the present study, the pharmacology of the P2Y 13 receptor and its differences with that of the P2Y 12 receptor have been further characterized in 1321N1 cells (binding of [ 33 P]2-methylthio-ADP (2MeSADP) and of GTPγ[ 35 S]), 1321N1 cells coexpressing Gα 16 [AG32 cells: inositol trisphosphate (IP 3 ) measurement, binding of GTPγ[ 35 S]) and Chinese hamster ovary (CHO)-K1 cells (cAMP assay)]. 2MeSADP was more potent than ADP in displacing [ 33 P]2MeSADP bound to 1321N1 cells and increasing GTPγ[ 35 S] binding to membranes prepared from the same cells. Similarly, 2MeSADP was more potent than ADP in stimulating IP 3 accumulation after 10 min in AG32 cells and increasing cAMP in pertussis toxin-treated CHO-K1 cells stimulated by forskolin. On the other hand, ADP and 2MeSADP were equipotent at stimulating IP 3 formation in AG32 cells after 30 s and inhibiting forskolininduced cAMP accumulation in CHO-K1 cells. These differences in potency cannot be explained by differences in degradation rate, which in AG32 cells was similar for the two nucleotides. When contaminating diphosphates were enzymatically removed and assay of IP 3 was performed after 30 s, ATP and 2MeSATP seemed to be weak partial agonists of the P2Y 13 receptor expressed in AG32 cells. The stimulatory effect of ADP on the P2Y 13 receptor in AG32 cells was antagonized by reactive blue 2, suramin, pyridoxal-phosphate-6-azophenyl-2′,4′disulfonic acid, diadenosine tetraphosphate, and 2-(propylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C67085MX), but not by N 6 -methyl 2′-deoxyadenosine 3′,5′-bisphosphate (MRS-2179) (up to 100 μM). The most potent antagonist was N 6 -(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (ARC69931MX) (IC 50 = 4 nM), which behaved in a noncompetitive way. The active metabolite of clopidogrel was unable to displace bound 2MeSADP at concentrations up to 2 μM.</description><subject>Adenosine Diphosphate - pharmacology</subject><subject>Adenosine Triphosphate - analogs &amp; derivatives</subject><subject>Adenosine Triphosphate - pharmacology</subject><subject>Animals</subject><subject>Cell Membrane - drug effects</subject><subject>Cell Membrane - metabolism</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Cyclic AMP - metabolism</subject><subject>Female</subject><subject>GTP-Binding Protein alpha Subunits, Gi-Go - pharmacology</subject><subject>Guanosine 5'-O-(3-Thiotriphosphate) - metabolism</subject><subject>Humans</subject><subject>Inositol Phosphates - metabolism</subject><subject>Kinetics</subject><subject>Receptors, Purinergic P2 - drug effects</subject><subject>Receptors, Purinergic P2 - metabolism</subject><subject>Thionucleotides - pharmacology</subject><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkE1Lw0AQhhdRbK3ePEsuekvc2ewneJGiVihYREFPy2a720SSbtwkSP31Bqp4Ggae92WeQegccAZA6HUT6ozTDDLA9ABNgRFIMQAcoinGhKdSsbcJOum6D4yBMomP0QSIBAacT9HNqjSxMTbUYVNZUyfzcTe2d7H6Nn0VtknwSV-6ZDE0ZpusyDvkybOzru1DPEVH3tSdO_udM_R6f_cyX6TLp4fH-e0yLcdr-lQaxsF7CVIZDMRRZgvBCSukN74QyoPNFWOemDWVWAnJnSKwtmNIFIKZfIau9r1tDJ-D63rdVJ11dW22LgydFnmulGB0BC9-waFo3Fq3sWpM3Ok_3xG43ANltSm_quh0---_05xq0OMf8x9xEmLJ</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>Marteau, Frederic</creator><creator>Le Poul, Emmanuel</creator><creator>Communi, David</creator><creator>Communi, Didier</creator><creator>Labouret, Catherine</creator><creator>Savi, Pierre</creator><creator>Boeynaems, Jean-Marie</creator><creator>Gonzalez, Nathalie Suarez</creator><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20030701</creationdate><title>Pharmacological Characterization of the Human P2Y13 Receptor</title><author>Marteau, Frederic ; Le Poul, Emmanuel ; Communi, David ; Communi, Didier ; Labouret, Catherine ; Savi, Pierre ; Boeynaems, Jean-Marie ; Gonzalez, Nathalie Suarez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h152t-8a561ff8189a012e45cb7625b8fafb79f1c3955f2ad4809786e921dc61f7b75a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenosine Diphosphate - pharmacology</topic><topic>Adenosine Triphosphate - analogs &amp; derivatives</topic><topic>Adenosine Triphosphate - pharmacology</topic><topic>Animals</topic><topic>Cell Membrane - drug effects</topic><topic>Cell Membrane - metabolism</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Cyclic AMP - metabolism</topic><topic>Female</topic><topic>GTP-Binding Protein alpha Subunits, Gi-Go - pharmacology</topic><topic>Guanosine 5'-O-(3-Thiotriphosphate) - metabolism</topic><topic>Humans</topic><topic>Inositol Phosphates - metabolism</topic><topic>Kinetics</topic><topic>Receptors, Purinergic P2 - drug effects</topic><topic>Receptors, Purinergic P2 - metabolism</topic><topic>Thionucleotides - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marteau, Frederic</creatorcontrib><creatorcontrib>Le Poul, Emmanuel</creatorcontrib><creatorcontrib>Communi, David</creatorcontrib><creatorcontrib>Communi, Didier</creatorcontrib><creatorcontrib>Labouret, Catherine</creatorcontrib><creatorcontrib>Savi, Pierre</creatorcontrib><creatorcontrib>Boeynaems, Jean-Marie</creatorcontrib><creatorcontrib>Gonzalez, Nathalie Suarez</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marteau, Frederic</au><au>Le Poul, Emmanuel</au><au>Communi, David</au><au>Communi, Didier</au><au>Labouret, Catherine</au><au>Savi, Pierre</au><au>Boeynaems, Jean-Marie</au><au>Gonzalez, Nathalie Suarez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological Characterization of the Human P2Y13 Receptor</atitle><jtitle>Molecular pharmacology</jtitle><addtitle>Mol Pharmacol</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>64</volume><issue>1</issue><spage>104</spage><epage>112</epage><pages>104-112</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>The P2Y 13 receptor has recently been identified as a new P2Y receptor sharing a high sequence homology with the P2Y 12 receptor as well as similar functional properties: coupling to G i and responsiveness to ADP ( Communi et al., 2001 ). In the present study, the pharmacology of the P2Y 13 receptor and its differences with that of the P2Y 12 receptor have been further characterized in 1321N1 cells (binding of [ 33 P]2-methylthio-ADP (2MeSADP) and of GTPγ[ 35 S]), 1321N1 cells coexpressing Gα 16 [AG32 cells: inositol trisphosphate (IP 3 ) measurement, binding of GTPγ[ 35 S]) and Chinese hamster ovary (CHO)-K1 cells (cAMP assay)]. 2MeSADP was more potent than ADP in displacing [ 33 P]2MeSADP bound to 1321N1 cells and increasing GTPγ[ 35 S] binding to membranes prepared from the same cells. Similarly, 2MeSADP was more potent than ADP in stimulating IP 3 accumulation after 10 min in AG32 cells and increasing cAMP in pertussis toxin-treated CHO-K1 cells stimulated by forskolin. On the other hand, ADP and 2MeSADP were equipotent at stimulating IP 3 formation in AG32 cells after 30 s and inhibiting forskolininduced cAMP accumulation in CHO-K1 cells. These differences in potency cannot be explained by differences in degradation rate, which in AG32 cells was similar for the two nucleotides. When contaminating diphosphates were enzymatically removed and assay of IP 3 was performed after 30 s, ATP and 2MeSATP seemed to be weak partial agonists of the P2Y 13 receptor expressed in AG32 cells. The stimulatory effect of ADP on the P2Y 13 receptor in AG32 cells was antagonized by reactive blue 2, suramin, pyridoxal-phosphate-6-azophenyl-2′,4′disulfonic acid, diadenosine tetraphosphate, and 2-(propylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C67085MX), but not by N 6 -methyl 2′-deoxyadenosine 3′,5′-bisphosphate (MRS-2179) (up to 100 μM). The most potent antagonist was N 6 -(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5′-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (ARC69931MX) (IC 50 = 4 nM), which behaved in a noncompetitive way. The active metabolite of clopidogrel was unable to displace bound 2MeSADP at concentrations up to 2 μM.</abstract><cop>United States</cop><pub>American Society for Pharmacology and Experimental Therapeutics</pub><pmid>12815166</pmid><doi>10.1124/mol.64.1.104</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0026-895X
ispartof Molecular pharmacology, 2003-07, Vol.64 (1), p.104-112
issn 0026-895X
1521-0111
language eng
recordid cdi_proquest_miscellaneous_73399754
source Free Full-Text Journals in Chemistry
subjects Adenosine Diphosphate - pharmacology
Adenosine Triphosphate - analogs & derivatives
Adenosine Triphosphate - pharmacology
Animals
Cell Membrane - drug effects
Cell Membrane - metabolism
CHO Cells
Cricetinae
Cyclic AMP - metabolism
Female
GTP-Binding Protein alpha Subunits, Gi-Go - pharmacology
Guanosine 5'-O-(3-Thiotriphosphate) - metabolism
Humans
Inositol Phosphates - metabolism
Kinetics
Receptors, Purinergic P2 - drug effects
Receptors, Purinergic P2 - metabolism
Thionucleotides - pharmacology
title Pharmacological Characterization of the Human P2Y13 Receptor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A32%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20Characterization%20of%20the%20Human%20P2Y13%20Receptor&rft.jtitle=Molecular%20pharmacology&rft.au=Marteau,%20Frederic&rft.date=2003-07-01&rft.volume=64&rft.issue=1&rft.spage=104&rft.epage=112&rft.pages=104-112&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/mol.64.1.104&rft_dat=%3Cproquest_pubme%3E73399754%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h152t-8a561ff8189a012e45cb7625b8fafb79f1c3955f2ad4809786e921dc61f7b75a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73399754&rft_id=info:pmid/12815166&rfr_iscdi=true